Actively Recruiting
Study of Fermented Protaetia brevitarsis Seulensis Powder to Treat Alcoholic Liver Disease in Adults
Led by Pusan National University Yangsan Hospital · Updated on 2025-06-04
30
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effects of Fermented Protaetia brevitarsis seulensis powder on liver function in adults with alcohol-induced liver disease. This randomized, double-blind, placebo-controlled study aims to assess liver health and safety of the supplement over an 8-week period. The study focuses on key liver enzymes and metabolic markers to better understand potential benefits for this condition. Participants are randomly assigned to one of two groups one group takes 4,000 mg of Fermented Protaetia brevitarsis seulensis powder daily, while the other group receives a placebo. Both groups follow their assigned regimen for 8 weeks, with the study designed to keep participants and researchers unaware of group assignments to ensure unbiased results. During the study, researchers measure gamma-glutamyl transferase, alanine aminotransferase, aspartate aminotransferase, and other metabolic parameters at the start, and after 4 and 8 weeks of treatment. They also assess fatigue severity over the 8-week period. This ongoing monitoring helps evaluate liver function changes and safety, with total participation lasting about 8 weeks.
CONDITIONS
Brief Title
Effect of Fermented Protaetia Brevitarsis Seulensis Powder on Alcohol-induced Liver Disease
Research Team
S
Sang Yeoup Lee, Professor
Y
Ye Le Lee
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here